Investment Research report

TSO3 Inc.

TSX: TOS / OTC: TSTIF
Previous Item
All Reports
TSO3 Inc.
Infected Investment Opportunity
Download Report

Research Overview

INDEX:
S&P 500
Sector:
Healthcare
Position:
Short
Date:
Aug 23, 2017

After conducting a forensic financial and accounting review, Spruce Point believes TSO3 Inc. (TSX: TOS/ OTC: TSTIF), a sterilization technology for medical devices in healthcare settings, relies heavily on its promotional past, is facing ongoing challenges with its product, and has end of market sales that are being buried by lack of disclosure. Based on our latest investigation, we estimate >80% downside risk. 

The report highlights several key concerns with the company, including:

  • We view the Company as an over-hyped Canadian healthcare stock that relies heavily on its endorsements 
  • Evidence of disclosure issues and obfuscation of actual end market sales
Downloads & More

Research Assets & Releases

Key Media Coverage

Nothing posted currently

Broadcast Coverage

Nothing posted currently

Join The Mailing List

Spruce Point Alerts & Updates

See the other side of the Wall Street hype machine.